Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
100% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $7.6K | $25.8K | $8.2K | $20.0K |
| Cost of revenue | $0 | $0 | $0 | $125 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | −$125 | $0 | $25.8K | $8.2K | $20.0K |
| Gross margin | — | — | — | — | 0.0% | 100.0% | 100.0% | 100.0% |
| R&D | $481.7K | $188.8K | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$3.9M | −$461.8K | −$250.0K | −$112.0K | −$74.7K | −$97.7K | −$63.2K | −$9.5K |
| EBITDA | −$1.3M | −$454.0K | −$250.0K | −$131.0K | −$152.0K | −$232.0K | −$124.9K | −$77.5K |
| Net income | −$3.6M | −$458.9K | −$480.0K | −$206.0K | −$259.0K | −$339.0K | −$124.9K | −$119.1K |
| Net margin | — | — | — | — | -3407.9% | -1311.9% | -1525.2% | -595.3% |
| EPS (diluted) | -45.43 | -11.59 | -7.83 | -0.92 | -0.32 | -0.00 | -0.00 | -0.00 |
Annual figures · source: Financial Modeling Prep
SOUTH AMERICAN GOLD CORP
No one on the platform currently holds SAGD.
No tracked institution reports a position in SAGD as of their last filing.
| Execution date | Ratio |
|---|---|
| 2015-08-27 | 1-for-2000reverse |
| 2008-01-22 | 6-for-1 |
No one on the platform has traded SAGD yet.
| $55269 |
| — |
| INLBItem 9 Labs Corp. | $0.00 | +0.00% | $70181 | — |
| INSDInstadose Pharma Corp. | $0.00 | +0.00% | $53193 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.